Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Oklahoma
M.D. Anderson Cancer Center
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Genentech, Inc.
Brigham and Women's Hospital
University of Utah
EMD Serono
UroGen Pharma Ltd.
ImmunityBio, Inc.
Tyra Biosciences, Inc
CG Oncology, Inc.
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Pangea Laboratory LLC
Janssen Research & Development, LLC
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
British Columbia Cancer Agency
EMD Serono
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
BeOne Medicines
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Astellas Pharma Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Exelixis
AbbVie
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Fox Chase Cancer Center
Hoosier Cancer Research Network
University of Southern California
Klus Pharma Inc.
Memorial Sloan Kettering Cancer Center